H.C. Wainwright Assumes Coverage of Insmed with Buy Rating
Analyst firm H.C. Wainwright & Co. has initiated coverage of Insmed with a Buy rating and a price target of $220.
Stocks · News reference
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
Insmed Incorporated announced its financial results for the third quarter of 2026 and provided an update on its business operations and guidance.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Insmed to Present at November and December 2026 Investor Conferences
Insmed Incorporated announced its upcoming participation in several investor conferences scheduled for November and December 2026.
Guggenheim Maintains Buy Rating on Insmed, Lowers Price Target to $201
Guggenheim has reiterated its Buy rating on Insmed Incorporated while adjusting its price target to $201 from $205.
Mizuho Adjusts Price Target on Insmed to $158 From $154
Mizuho has adjusted its price target for Insmed Incorporated to $158 from $154 while maintaining an Outperform rating.
Guggenheim Maintains Buy on Insmed, Lowers Price Target to $201
Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday
Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and Crocs, despite the Dow falling 150 points.